Embed Size (px)
Citation preview
Presenter Anna Daily Ph.D.-Senior Scientist
March 9, 2012Breast Health Providers Conference
Why A New Approach to Breast Cancer Screening?
Of women age 40 and over with insurance coverage only 50% participate in yearly screenings.
Why women don’t participate: Dense Breast Tissue Lack of Facility Access Some find procedure painful Cost prohibitive for uninsured False Positive rate of 5% per exam= 50%
over per patient lifetime
Ascendant Diagnostics is Developing:
An inexpensive, highly accurate test that can diagnose cancer at earlier stages is highly sought after
A Low Cost
Non-Invasive
Screening Method for Breast Cancer
Detects proteins present in tear samples
Based on technology licensed from UAMS
Why Tears?Easy and Quick to CollectPain FreeNon-invasiveContain Protein in High ConcentrationsEasy to Prep for Test
Cancer
No Cancer
SELDI TOF MS
Bioinformatic analysisDiagnostic fingerprintNew targets
Cancer
No Cancer
SELDI TOF MS
Bioinformatic analysisDiagnostic fingerprintNew targets
Analyze Tears byMass Spectrometry
Collect Tear Sample Look for Differences
Mass Spectrometry
Private Industry Quest LabCorp PeaceHealth Labs
Drug TestingMonitoring Pain MedicationMonitor metabolic disorders
Separates samples based on Size4045.798
14691.861
16421.046
17439.8153122.430
8211.19511719.514
13899.559
0.0
0.5
1.0
1.5
2.0
2.5
4x10
Inte
ns.
[a.u
.]
2000 4000 6000 8000 10000 12000 14000 16000 18000 20000m/z
Increasing sizeIn
tensi
tyB
igger
peak=
more
pro
tein
Genomics vs. Proteomics
DNA Sequences Protein Structure and Function
Predictive of RiskNot Diagnostic Diagnostic
Imaging is the Gold Standard
TechniqueIonizing Radiatio
n
Breast Compressio
n
False Negative
Rate
False Positive
Rate
Mammography Yes YES 10-30% Up to 75%
Ultrasound No No >30% Up to 65%
PET Yes No 15-25% 25 to 75%
MRI No No 1-15% 25 to 75%
Tear Testing80% Sensitive75% Specific
90% Sensitive90% Specific
$75.00 per test vs. $200 for mammogram
Regulatory Pathway
CLIA: Clinical Laboratory Improvements Amendment
Timeline
2011 2012 2013 2014 2015
Licensed Technology;
Business Case;
Established Strategic
Partnerships
Protein Biomarker
Identification; 2 cohorts of 300 patients;
establish more
partnerships; develop CLIA
protocol
Clinical Validation; Marketing and Sales
Team Build up
Contract Development
of POC Lab on a Chip
and Contract Development of Reagents;
Sales and Mktg.
Other Cancer
biomarkers; lines
between treatment
and level of protein
Collaborations
• The Breast Center – established February 2012– 300 tear samples over the next 2 years
• Winthrop P. Rockefeller Cancer Institute Women’s clinic (UAMS)– In Progress– 300 tear samples over the next 2 years
• Peace Health Labs– Established August 2011– Aid and in development and testing of CLIA lab protocol
• University of Arkansas Statewide Mass Spectrometry Facility– established February 2011– Acess to mass spectrometry instrumentation– Collabroations on Grant applications– Aid in development of CLIA based protocol
Management Team
Scientific Advisory Board
Contact Information Omid Moghadam CEO 479-571-2592 [email protected]
Anna Daily Ph.D. Scientist [email protected]
